4z6i: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Crystal structure of BRD9 bromodomain in complex with a substituted valerolactam quinolone ligand== | ==Crystal structure of BRD9 bromodomain in complex with a substituted valerolactam quinolone ligand== | ||
<StructureSection load='4z6i' size='340' side='right' caption='[[4z6i]], [[Resolution|resolution]] 1.95Å' scene=''> | <StructureSection load='4z6i' size='340' side='right' caption='[[4z6i]], [[Resolution|resolution]] 1.95Å' scene=''> | ||
| Line 4: | Line 5: | ||
<table><tr><td colspan='2'>[[4z6i]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4Z6I OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4Z6I FirstGlance]. <br> | <table><tr><td colspan='2'>[[4z6i]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4Z6I OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4Z6I FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4L3:TERT-BUTYL+[(2R,3S)-1-(1,4-DIMETHYL-2-OXO-1,2-DIHYDROQUINOLIN-7-YL)-6-OXO-2-PHENYLPIPERIDIN-3-YL]CARBAMATE'>4L3</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4L3:TERT-BUTYL+[(2R,3S)-1-(1,4-DIMETHYL-2-OXO-1,2-DIHYDROQUINOLIN-7-YL)-6-OXO-2-PHENYLPIPERIDIN-3-YL]CARBAMATE'>4L3</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4z6i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4z6i OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4z6i RCSB], [http://www.ebi.ac.uk/pdbsum/4z6i PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4z6i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4z6i OCA], [http://pdbe.org/4z6i PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4z6i RCSB], [http://www.ebi.ac.uk/pdbsum/4z6i PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4z6i ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
| Line 16: | Line 17: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 4z6i" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Bromodomain-containing protein|Bromodomain-containing protein]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 13:01, 10 March 2017
Crystal structure of BRD9 bromodomain in complex with a substituted valerolactam quinolone ligandCrystal structure of BRD9 bromodomain in complex with a substituted valerolactam quinolone ligand
Structural highlights
Function[BRD9_HUMAN] May play a role in chromatin remodeling and regulation of transcription. Publication Abstract from PubMedThe bromodomain-containing proteins BRD9 and BRD7 are part of the human SWI/SNF chromatin-remodeling complexes BAF and PBAF. To date, no selective inhibitor for BRD7/9 has been reported despite its potential value as a biological tool or as a lead for future therapeutics. The quinolone-fused lactam LP99 is now reported as the first potent and selective inhibitor of the BRD7 and BRD9 bromodomains. Development of LP99 from a fragment hit was expedited through balancing structure-based inhibitor design and biophysical characterization against tractable chemical synthesis: Complexity-building nitro-Mannich/lactamization cascade processes allowed for early structure-activity relationship studies whereas an enantioselective organocatalytic nitro-Mannich reaction enabled the synthesis of the lead scaffold in enantioenriched form and on scale. This epigenetic probe was shown to inhibit the association of BRD7 and BRD9 to acetylated histones in vitro and in cells. Moreover, LP99 was used to demonstrate that BRD7/9 plays a role in regulating pro-inflammatory cytokine secretion. LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor.,Clark PG, Vieira LC, Tallant C, Fedorov O, Singleton DC, Rogers CM, Monteiro OP, Bennett JM, Baronio R, Muller S, Daniels DL, Mendez J, Knapp S, Brennan PE, Dixon DJ Angew Chem Int Ed Engl. 2015 May 18;54(21):6217-21. doi: 10.1002/anie.201501394. , Epub 2015 Apr 13. PMID:25864491[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||